朱先任;郑欣;李东亚;卜祥博;郭开今;李洪伟;

• 1:徐州医科大学研究生学院
• 2:徐州医科大学附属医院骨科

摘要(Abstract)：

[目的]探讨重复静脉应用氨甲环酸(TXA)对双节段腰椎后路椎间融合术(PLIF)患者的有效性和安全性。[方法]收集2015年1月～2018年9月在本院行双节段腰椎后路椎间融合手术患者90例。按照TXA的不同用法,将患者分为对照组,单次给药组和重复给药组。记录并比较各组患者手术时间、总失血量、隐性失血量、术后引流量、输血率、静脉血栓栓塞发生率以及切口感染情况。[结果]重复给药组总失血量[(1 086.80±212.97) ml]和术后引流量[(315.17±75.47) ml]均明显低于对照组[(1 353.53±310.83) ml,(430.50±88.46) ml]和单次给药组[(1269.06±293.29) ml,(373.33±62.07) ml](P<0.05)。单次给药组术后引流量[(373.33±62.07) ml]少于对照组[(430.50±88.46) ml](P<0.05);重复给药组隐性失血量[(443.13±213.95) ml]明显少于对照组[(609.37±298.43) ml](P<0.05)。重复给药组术后第3 d Hb值[(108.20±12.55) g/L]和Hct值[(30.64±3.26)%]明显高于对照组[(100.13±13.19) g/L,(28.51±3.74)%],差异有统计学意义(P<0.05)。所有患者均未出现肺栓塞和切口感染,肌间静脉血栓发生率和输血率各组间比较,差异无统计学意义(P>0.05)。[结论]氨甲环酸可减少腰椎后路椎间融合术患者的失血量,重复静脉应用氨甲环酸可进一步减少围手术期总失血量、隐性失血量,减少术后血红蛋白丢失,而不增加血栓发生的风险。

关键词(KeyWords)： 腰椎后路椎间融合术;氨甲环酸;隐性失血;引流量

Abstract:

Keywords:

基金项目(Foundation): 江苏省卫计委青年医学人才项目(编号:QNRC2016801)

作者(Author): 朱先任;郑欣;李东亚;卜祥博;郭开今;李洪伟;

Email:

DOI:

参考文献(References)：

• [1]Hur SR, Huizenga BA, Major M. Acute normovolemic hemodilution combined with hypotensive anesthesia and other techniques to avoid homologous transfusion in spinal fusion surgery[J]. Spine,1992, 17(8):867-873.
• [2]Hu SS. Blood loss in adult spinal surgery[J]. Eur Spine J, 2004,13(Suppl 1):3-5.
• [3]Fillingham YA, Ramkumar DB, Jevsevar DS, et al. Tranexamic acid use in total joint arthroplasty:the clinical practice guidelines endorsed by the american association of hip and knee surgeons, american society of regional anesthesia and pain medicine, american academy of orthopaedic surgeons, hip society, and knee society[J]. J Arthroplasty, 2018, 33(10):3065-3069.
• [4]卜国云,吴叶,邓树才,等.切口内应用氨甲环酸对腰椎后路椎间融合术后失血的影响[J].中国矫形外科杂志, 2014, 22(18):1637-1641.
• [5]Ren Z, Li S, Sheng L, et al. Efficacy and safety of topical use of tranexamic acid in reducing blood loss during primary lumbar spinal surgery:a retrospective case control study[J]. Spine(Phila Pa1976), 2017, 42(23):1779-1784.
• [6]Kim KT, Kim CK, Kim YC, et al. The effectiveness of low-dose and high-dose tranexamic acid in posterior lumbar interbody fusion:a double-blinded, placebo-controlled randomized study[J].Eur Spine J, 2017, 26(11):2851-2857.
• [7]Kushioka J, Yamashita T, Okuda S, et al. High-dose tranexamic acid reduces intraoperative and postoperative blood loss in posterior lumbar interbody fusion[J]. J Neurosurg Spine, 2017, 26(3):363-367.
• [8]Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults[J]. Surgery, 1962, 51(2):224-232.
• [9]Gross J. Estimating allowable blood loss:corrected for dilution[J].Anesthesiology, 1983, 58(3):277-280.
• [10]Neilipovitz DT. Tranexamic acid for major spinal surgery[J]. Eur Spine J, 2004, 13(Suppl 1):62-65.
• [11]张雅宾,李鹏,王义国,等.两种减压方法治疗腰椎退行性疾病的失血量比较[J].解放军医学院学报, 2016, 37(4):328-331.
• [12]Dunn CJ, Goa KL. Tranexamic acid:a review of its use in surgery and other indications[J]. Drugs, 1999, 57(6):1005-1032.
• [13]Endres S, Heinz M, Wilke A. Efficacy of tranexamic acid in reducing blood loss in posterior lumbar spine surgery for degenerative spinal stenosis with instability:a retrospective case control study[J]. BMC Surg, 2011, 11(1):29.
• [14]Hiippala S, Strid L, Wennerstrand M, et al. Tranexamic acid(Cyklokapron)reduces perioperative blood loss associated with total knee arthroplasty[J]. Br J Anaesthesia, 1995, 74(5):534-537.